Skip to Main Content


Skip Nav Destination



J Immunol (2019) 203 (7): 1679–1680.


J Immunol (2019) 203 (7): 1681–1682.


J Immunol (2019) 203 (7): 1683–1684.


J Immunol (2019) 203 (7): 1687–1692.

  • More than 80% of H chain–based clones contained cells expressing consistent L chains.

  • L chain junction diversity did not further refine these H chain–based clones.

  • Leveraging additional H chain features could improve B cell clonal inference.


J Immunol (2019) 203 (7): 1693–1700.

  • Human-derived IgE and allergens were used to study IgE-mediated cellular activation.

  • Multivalent allergens can effectively cross-link low-affinity IgE–FcεRI complexes.

  • Epitope orientation and spacing can improve IgE–FcεRI cross-linking.

J Immunol (2019) 203 (7): 1701–1714.

  • A mouse model of granuloma induced by intrathecal morphine was established.

  • Mast cell–specific receptor MrgprB2 is essential for granuloma pathogenesis.

  • Activation of MrgprB2 in mast cells promote granuloma-related cell recruitment.


J Immunol (2019) 203 (7): 1715–1729.

  • CD180 Ag targeting facilitates Ag presentation by B cells to CD4+ T cells.

  • Immature B cells are sufficient for TFH cell maturation.

  • Compared with CD180, CD40 targeting induces slower and lower-affinity IgG responses.

J Immunol (2019) 203 (7): 1730–1742.

  • UCH-L1 expression and activity in DCs are regulated by immune stimuli.

  • Cross-priming of the CD8 T cell response is affected by UCH-L1.

  • MHC I recycling for cross-presentation is promoted by UCH-L1.


J Immunol (2019) 203 (7): 1743–1752.

  • EAE but not pregnancy increases TCRβ clonality in Tcon and Treg.

  • Pregnancy is required for expansion of TRBV13-2–positive Treg.

  • Pregnancy is required for expansion of EAE-related Treg clonotypes.

J Immunol (2019) 203 (7): 1753–1765.

  • Annexin A1 expression is reduced in T cells from naive-to-treatment RRMS subjects.

  • Annexin A1 levels correlate inversely with disease clinical score.

  • Annexin A1 reduces T cell activation, proliferation, and glycolysis.

J Immunol (2019) 203 (7): 1766–1775.

  • Increased mTNF and defect in M2-like macrophages are biomarkers specific to RA.

  • Increase in miR155 is responsible for this defect and could be a new target for therapeutic strategies.

J Immunol (2019) 203 (7): 1776–1785.

  • CD14+ monocytes are the main producers of IL-23 in LPS-stimulated human PBMCs.

  • Immunoproteasome inhibition selectively kills human monocytes.

  • The immunoproteasome is required to maintain protein turnover in monocytes.

J Immunol (2019) 203 (7): 1786–1792.

  • Treg cells regulate PF4/heparin-specific Ab production through IL-10.

  • Treg cells are important for the pathogenesis of heparin-induced thrombocytopenia.


J Immunol (2019) 203 (7): 1793–1807.

  • Amniotic fluid T cells are of fetal origin and functional in preterm gestations.

  • Amniotic fluid T cells are increased in women with idiopathic preterm labor and birth.

  • Intra-amniotic injection of activated neonatal T cells induces preterm birth in mice.


J Immunol (2019) 203 (7): 1808–1819.

  • In vivo treatment with α-GalCer results in hepatic pre-mNK cell expansion.

  • α-GalCer–induced pre-mNK cell expansion is mediated by IL-12 and IL-18.

  • α-GalCer–transactivated pre-mNK cells have tumoricidal/antimetastatic activities.

J Immunol (2019) 203 (7): 1820–1829.

  • ATG16L2-deficient mice are viable and exhibit intact canonical autophagy.

  • Intestinal infection reveals ATG16L2–(epithelial) ATG16L1 genetic interaction.

J Immunol (2019) 203 (7): 1830–1844.

  • AhR activation leads to induction of MDSCs with immunosuppressive activity.

  • AhR-mediated induction of MDSCs is regulated by microRNA that target CXCR2.

J Immunol (2019) 203 (7): 1845–1856.

  • CgCLec-HTM was associated with CgSyk to mediate the ERK–Rel pathway.

  • CgERK interacted with CgRel to induce CgRel nuclear translocation.

  • The CgCLec-HTM–mediated pathway induced CgIL-17 and CgTNF production.

J Immunol (2019) 203 (7): 1857–1866.

  • pM doses of CCL2 are effective in suppressing MOG-induced EAE.

  • The modulation of EAE by CCL2 is associated with downregulation of Th1/Th17 cells.

  • pM levels of CCL2 induce formation of highly functional Tregs.


J Immunol (2019) 203 (7): 1867–1881.

  • LSD1 is necessary for marginal zone B cell development.

  • LSD1 represses the follicular B cell and myeloid programs.

  • With noncanonical NF-κB, LSD1 regulates marginal zone B cell development.


J Immunol (2019) 203 (7): 1882–1896.

  • Emergence of class I/II and Ag receptor genes is proposed via comparative genomics.

  • Nonrearranging Ag receptor–like genes were identified in MHC paralogous regions.

  • Ancient translocation of an MHC genomic region including CD1 genes was discovered and named “MHCtrans.”


J Immunol (2019) 203 (7): 1897–1908.

  • Sepsis induces transcription of suppressive genes in innate and adaptive immune cells.

  • Sepsis, trauma, and cancer share many common immunosuppressive mechanisms.

  • Monocytic transcriptomic changes during sepsis are markedly suppressive.

J Immunol (2019) 203 (7): 1909–1917.

  • Active immunization with DJ NS1 plus NS3 induces a strong Ab response.

  • Active immunization with DJ NS1 plus NS3 induces specific T cell responses.

  • Combined DJ NS1 plus NS3 provides enhanced protection against DENV infection.

J Immunol (2019) 203 (7): 1918–1929.

  • Asp53 residue of β2M is important in forming a complex with Met93 of ESAT-6.

  • SM09 and SM15 rescued ESAT-6–mediated downregulation of MHC class I Ag presentation.

  • SM09 and SM15 inhibited survival of M. tuberculosis inside the macrophage.


J Immunol (2019) 203 (7): 1930–1942.

  • More evidence is provided for the rationale behind the name of chicken IRF7.

  • Chicken IRF7 participates in both MAVS- and STING-mediated IFN-β regulation.

  • Chicken STING mediates the activation of IRF7 through a conserved SLQxSyS motif.

J Immunol (2019) 203 (7): 1943–1951.

  • UBL4A is a novel IFN-stimulated gene.

  • UBL4A positively regulates innate immune response.

  • UBL4A interacts with and targets TRAF6 for K63-linked ubiquitination.

J Immunol (2019) 203 (7): 1952–1960.

  • In adults, increased IL-33 expression in the lungs per se is not pathologic.

  • In neonates, increased IL-33 results in severe peripheral lung pathology.

  • Pathologic effects of IL-33 in the lungs are age dependent.

J Immunol (2019) 203 (7): 1961–1972.

  • MSC EV may stimulate increased antimicrobial activity during bacterial pneumonia.

  • Increased antimicrobial activity is associated with increased LTB4 production.

  • MSC EV may increase LTB4 production via transfer of miR145 to target cells.

J Immunol (2019) 203 (7): 1973–1980.

  • Plasma FB levels are elevated in patients with symptomatic and asymptomatic AS.

  • High FB and Bb levels are associated with adverse outcome in severe symptomatic AS.

  • FB may be involved in AS pathogenesis and could operate in the early disease phase.

J Immunol (2019) 203 (7): 1981–1988.

  • NK activation receptor–dependent IFN-γ requires additional signals.

  • Cytokine stimulation, but not activation receptor stimulation, induces Ifng transcription.

  • Activation receptor ligation stimulates IFN-γ translation through TPL2.


J Immunol (2019) 203 (7): 1989–1998.

  • Specific Jun family members cooperate with BATF in promoting IL-9 in Th9 cells.

  • Bach2 cooperates with BATF to promote IL-9 in Th9 cells.

  • Expression and function of bZIP factors dictate IL-9 activation in Th17 cells.


J Immunol (2019) 203 (7): 1999–2010.

  • Many primary human cancers frequently downregulate the transcription factor IRF2.

  • IRF2 loss causes an immune evasion phenotype of low MHC-I and high PD-L1.

  • The MHC-I defect in IRF2-low cells can be restored upon IFN stimulation.

J Immunol (2019) 203 (7): 2011–2019.

  • Anti-OX40 treatment does not impair TIL Treg suppressive function.

  • OX40 ligation enhances Treg and Tconv proliferation through Tconv cell IL-2 secretion.

  • TIL Tregs proliferate and produce Th1 cytokines after anti-OX40 treatment.


J Immunol (2019) 203 (7): 2020.
J Immunol (2019) 203 (7): 2021–2022.
J Immunol (2019) 203 (7): 2023–2024.
Close Modal

or Create an Account

Close Modal
Close Modal